By Elena Vardon
Pharmaceutical giant Novo Nordisk said it will invest more than 16 billion Danish kroner ($2.34 billion) in its French production site as it seeks to meet rising demand for its blockbuster obesity and diabetes treatments.
The Danish company, which makes the Wegovy obesity drug and diabetes drug Ozempic, said Thursday that the…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
Read the full article here